Non–Small Cell Lung Cancer Clinical Care

home / insights / nsclc-clinical-care

Episodes

Molecular Testing in Patients With NSCLC

March 15th 2019EP. 1: Molecular Testing in Patients With NSCLC

Next-Generation Sequencing in Patients With NSCLC

March 15th 2019EP. 2: Next-Generation Sequencing in Patients With NSCLC

Nondriver NSCLC Treatment Factors

March 15th 2019EP. 3: Nondriver NSCLC Treatment Factors

Nondriver NSCLC Trials: KEYNOTE-189, -407, -024

March 15th 2019EP. 4: Nondriver NSCLC Trials: KEYNOTE-189, -407, -024

NSCLC Treatment: Low PD-L1 Status and Chemotherapy

March 15th 2019EP. 5: NSCLC Treatment: Low PD-L1 Status and Chemotherapy

Metastatic NSCLC I-O Combination Therapies

March 15th 2019EP. 6: Metastatic NSCLC I-O Combination Therapies

Combination I-O Treatment Factors & Preference

March 15th 2019EP. 7: Combination I-O Treatment Factors & Preference

$Pembrolizumab for Relapsed/Refractory Metastatic NSCLC$

March 15th 2019EP. 8: Pembrolizumab for Relapsed/Refractory Metastatic NSCLC

The REVEL Trial and Subanalysis

March 15th 2019EP. 9: The REVEL Trial and Subanalysis

$Ramucirumab for Relapsed-Refractory Metastatic NSCLC$

March 15th 2019EP. 10: Ramucirumab for Relapsed-Refractory Metastatic NSCLC

The Impact of <i>EGFR</i> TKI on Nonsquamous NSCLC

March 15th 2019EP. 11: The Impact of <i>EGFR</i> TKI on Nonsquamous NSCLC

ALK Inhibitors and BRAF/MEK Inhibitors for NSCLC

March 15th 2019EP. 12: ALK Inhibitors and BRAF/MEK Inhibitors for NSCLC

The Changing Landscape of NSCLC Clinical Care

March 15th 2019EP. 13: The Changing Landscape of NSCLC Clinical Care

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions